Last reviewed · How we verify
NCT03675139
MPA Versus Dydrogesterone for Management of Endometrial Hyperplasia Without Atypia
Phase 3 trial testing Medroxyprogesterone Acetate in Endometrial Hyperplasia Without Atypia in 471 participants. Completed in 15 May 2022.
14 May 2022
Quick facts
| Lead sponsor | Xiaojun Chen |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 471 |
| Start date | 26 February 2019 |
| Primary completion | 14 May 2022 |
| Estimated completion | 15 May 2022 |
| Sites | 1 location across China |
Drugs / interventions tested
- Medroxyprogesterone Acetate — full drug profile →
- Dydrogesterone 10 MG — full drug profile →
Conditions studied
- Endometrial Hyperplasia Without Atypia — all drugs for Endometrial Hyperplasia Without Atypia →
Sponsor
Xiaojun Chen — full company profile →
Who can join
Adults 18 to 50, female only, with Endometrial Hyperplasia Without Atypia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To compare the efficacy of Medroxyprogesterone Acetate with dydrogesterone in patients having endometrial hyperplasia (EH) without atypia.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Progestins as Anticancer Drugs and Chemosensitizers, New Targets and Applications.
Fedotcheva TA, Fedotcheva NI, Shimanovsky NL. · · 2021 · cited 17× · PMID 34683909 · DOI 10.3390/pharmaceutics13101616
Verify or expand the search:
- PubMed search for NCT03675139
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Medroxyprogesterone Acetate
Trials testing the same drug.
- NCT05255653 — Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features · Phase 2, PHASE3 · recruiting
- NCT04654741 — The Rate of Embryo Euploidy in Progestin-primed Ovarian Stimulation Cycles · Phase 4 · unknown
- NCT03018249 — Medroxyprogesterone Acetate With or Without Entinostat Before Surgery in Treating Patients With Endometrioid Endometrial · EARLY_PHASE1 · completed
Other Xiaojun Chen trials
Trials by the same sponsor.
- NCT05316935 — GnRHa + Letrozole in Non-obese Progestin-insensitive Endometrial Cancer and Atypical Hyperplasia Patients · Phase 2, PHASE3 · recruiting
- NCT06379113 — GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients · Phase 2, PHASE3 · recruiting
- NCT06390904 — GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Atypical Hyperplasia Patients · Phase 2, PHASE3 · active not recruiting
- NCT05316493 — Weight Management Plus LNG-IUS/Megestrol Acetate in Endometrial Atypical Hyperplasia · Phase 2, PHASE3 · recruiting
- NCT05316467 — Weight Management Plus Megestrol Acetate in Early-stage Endometrioid Carcinoma · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03675139 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xiaojun Chen
- Last refreshed: 17 February 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03675139.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing